Sugi Predict

Sugi Predict / Compounds / SCHEMBL1770075

SCHEMBL1770075

SCHEMBL1770075

O=c1c(O)cc(-c2cccc(F)c2)cn1Cc1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 3/20 0.47
▸ CNR2 P34972 3/20 0.47
▸ ALDH1A1 P00352 1/20 0.45
▸ LMNA P02545 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ EGLN1 Q9GZT9 2/20 0.43
▸ CYP11B1 P15538 2/20 0.43
▸ CYP11B2 P19099 2/20 0.43
▸ VEGFA P15692 1/20 0.43
▸ ICMT O60725 2/20 0.42
▸ SERPINE1 P05121 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ MAPT P10636 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ GRM2 Q14416 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1770173 0.92 EGLN1 (0.50) CNR1CNR2ALDH1A1LMNASMN1; SMN2
SCHEMBL1770422 0.91 MKNK1 (0.46) ALDH1A1LMNASMN1; SMN2EGLN1ICMT
SCHEMBL1769986 0.90 LMNA (0.54) CNR1CNR2ALDH1A1LMNASMN1; SMN2
SCHEMBL1770259 0.88 EGLN1 (0.56) ALDH1A1LMNASMN1; SMN2EGLN1ICMT
SCHEMBL1770253 0.87 BRD4 (0.46) CNR1CNR2ALDH1A1LMNASMN1; SMN2
SCHEMBL1770368 0.85 EGLN1 (0.53) ALDH1A1LMNASMN1; SMN2EGLN1THRB
SCHEMBL1770023 0.83 MAPT (0.56) CNR1CNR2ALDH1A1LMNASMN1; SMN2
SCHEMBL1770483 0.83 PTGER3 (0.48) ALDH1A1SMN1; SMN2ICMTUSP2CYP1A2
SCHEMBL1770932 0.82 COMT (0.42) CNR2ALDH1A1SMN1; SMN2ICMTMAPT
SCHEMBL1770704 0.81 EGLN1 (0.61) CNR1CNR2LMNASMN1; SMN2EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC (US) 2022-06-16 — — US disclosed
EP-3698794-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS Aerpio Therapeutics, Inc. (US) 2020-08-26 — — EP disclosed
US-10562854-B2 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS, INC. (US) 2020-02-18 — — US disclosed
EP-3603644-A1 PROLYL HYDROXYLASE INHIBITORS Aerpio Therapeutics, Inc. (US) 2020-02-05 — — EP disclosed
EP-2952192-B1 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC (US) 2019-05-15 — — EP disclosed
US-20190055198-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2019-02-21 — — US disclosed
US-20170298019-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2017-10-19 — — US disclosed
EP-2853265-B1 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha AERPIO THERAPEUTICS INC (US) 2017-07-26 — — EP disclosed
US-9540326-B2 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS, INC. (US) 2017-01-10 — — US disclosed
EP-2496082-B1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA AERPIO THERAPEUTICS INC (US) 2016-10-12 — — EP disclosed
US-8309537-B2 Compositions and methods for treating colitis AERPIO THERAPEUTICS INC. (US) 2012-11-13 — — US disclosed
EP-2496082-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA Aerpio Therapeutics Inc. (US) 2012-09-12 — — EP disclosed
EP-2496084-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS Aerpio Therapeutics Inc. (US) 2012-09-12 — — EP disclosed
EP-2496236-A1 PROLYL HYDROXYLASE INHIBITORS Aerpio Therapeutics Inc. (US) 2012-09-12 — — EP disclosed
WO-2011057121-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AKEBIA THERAPEUTICS INC. (US) 2011-05-12 — — WO disclosed
US-20110110961-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed
US-20110111058-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed
WO-2011057112-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA AKEBIA THERAPEUTICS INC. (US) 2011-05-12 — — WO disclosed
WO-2011057115-A1 PROLYL HYDROXYLASE INHIBITORS AKEBIA THERAPEUTICS INC. (US) 2011-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298019-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 CNR1 1896/4885CNR2 1067/4885ALDH1A1 652/4885
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS ALPI, SI, SLC10A2 CNR1 879/4885CNR2 374/4885ALDH1A1 780/4885
US-20190055198-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 CNR1 1896/4885CNR2 1067/4885ALDH1A1 652/4885
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 CNR1 1896/4885CNR2 1067/4885ALDH1A1 652/4885
US-20110111058-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA HIF1A, HIF1AN, EGLN3 CNR1 3038/4885CNR2 3057/4885ALDH1A1 505/4885
US-20110110961-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 CNR1 1896/4885CNR2 1067/4885ALDH1A1 652/4885
US-10562854-B2 Prolyl hydroxylase inhibitors HIF1AN, HIF1A, EGLN2 CNR1 1896/4885CNR2 1067/4885ALDH1A1 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.